NEW YORK, April 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-s ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's drug approval process [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from October 31, 2022, to August 2, 2024 [2]. - Allegations include that the company made materially false statements and failed to disclose critical information regarding the Phase 3 Sierra trial data and its implications for FDA approval of the Iomab-B BLA [2]. Allegations Against the Company - The complaint states that the data from the Phase 3 Sierra trial was unlikely to meet FDA guidelines for approval [2]. - Additional analyses provided to the FDA to support the Iomab-B BLA were also unlikely to satisfy the FDA's requirements [2]. - As a result, the FDA was expected to refuse to review the Iomab-B BLA or deny approval if it did consider the application [2]. - The company's positive statements about its business and prospects were deemed materially misleading [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 27, 2025, to participate in the case [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software [3]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Solaris Energy Infrastructure, Actinium Pharmaceuticals, Bakkt Holdings, and Cerevel Therapeutics, with specific allegations of misleading statements and omissions of material facts regarding their business operations and prospects [1]. Solaris Energy Infrastructure, Inc. (NYSE: SEI) - Class period is from July 9, 2024, to March 17, 2025, with a lead plaintiff deadline of May 27, 2025 [2]. - Allegations include failure to disclose that Mobile Energy Rentals LLC had minimal corporate history, lacked a diversified earnings stream, and was co-owned by a convicted felon associated with turbine-related fraud [2]. - Claims that Solaris overstated commercial prospects from an acquisition and inflated profitability metrics by not properly depreciating turbines, leading to materially misleading statements [2]. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - Class period is from October 31, 2022, to August 2, 2024, with a lead plaintiff deadline of May 26, 2025 [3]. - The complaint alleges that Actinium made false claims regarding the strength of data submitted to the FDA for its Biologics License Application for Iomab-B, later admitting the need for additional clinical trials [3]. - Public statements were deemed materially misleading, resulting in investor damages when the truth was revealed [3]. Bakkt Holdings, Inc. (NYSE: BKKT) - Class period is from March 25, 2024, to March 17, 2025, with a lead plaintiff deadline of June 2, 2025 [4]. - Allegations include misrepresentation of the stability and diversity of crypto services revenue, which was heavily reliant on a single contract with Webull [4]. - Positive statements about the company's business were claimed to be materially misleading due to undisclosed dependencies [4]. Cerevel Therapeutics Holdings, Inc. (CERE) - Class period is from October 11, 2023, to August 1, 2024, with a lead plaintiff deadline of June 3, 2025 [6]. - The complaint alleges that Cerevel's offering documents omitted material facts about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [6]. - Claims that Cerevel's controlling shareholder acquired shares at an artificially depressed price while possessing nonpublic information, leading to a substantial windfall when AbbVie announced the acquisition at $45 per share [6][7].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Actinium Pharmaceuticals, Inc. related to misrepresentation of clinical trial data and its implications for FDA approval of Iomab-B BLA [1][2]. Group 1: Legal Investigation - Kuehn Law is looking into whether Actinium Pharmaceuticals' officers and directors failed to fulfill their fiduciary responsibilities to shareholders [1]. - The investigation stems from a federal securities lawsuit alleging that insiders misrepresented or failed to disclose critical information regarding the Sierra Trial data and its compliance with FDA guidelines [2]. Group 2: FDA Approval Concerns - The lawsuit claims that the data from the Sierra Trial is unlikely to meet FDA standards for the acceptance and approval of Iomab-B BLA [2]. - Additional analyses provided to the FDA, which were intended to show improved Overall Survival, are also said to be insufficient for FDA approval [2]. - As a result of these issues, the FDA may refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. Group 3: Shareholder Implications - Positive statements made by the company regarding its business and prospects are alleged to be materially misleading and lack a reasonable basis due to the aforementioned issues [2]. - Shareholders who purchased ATNM shares prior to October 31, 2022, are encouraged to contact Kuehn Law for potential legal recourse [3].

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 26, 2025 lead plaintiff deadline. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an ab ...

LOS ANGELES, April 15, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Actinium Pharmaceuticals, Inc. ("Actinium " or the "Company") (NYSE: ATNM) investors of a class action representing investors that bought securities between October 31, 2022 to August 2, 2024, inclusive (the "Class Period"). Capri investors have until May 27, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their l ...

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies.For more information, submit a form, email attorney Aaron Dumas, ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements related to the company's Iomab-B BLA application [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Actinium and its executives made false or misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA, which could lead to significant investor losses [5]. Group 2: Stock Performance and Market Reaction - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped by $3.69, or nearly 60%, closing at $2.48 on August 5, 2024 [6][7]. - The decline in stock price was attributed to the market's reaction to the company's regulatory update, indicating that the initial data from the Sierra Trial was unlikely to meet FDA guidelines [5][6]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8].

NEW YORK, April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-s ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's Iomab-B BLA application to the FDA [1][2]. Group 1: Allegations - The complaint alleges that during the class period from October 31, 2022, to August 2, 2024, the defendants made materially false and misleading statements regarding the Phase 3 Sierra trial data [2]. - It is claimed that the data from the Sierra trial was unlikely to meet FDA guidelines for the acceptance and approval of the Iomab-B BLA [2]. - The additional analyses provided to the FDA to mitigate the poor overall survival data from the Sierra trial were also unlikely to satisfy FDA requirements [2]. - As a result of these issues, the FDA was expected to refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. - The defendants' positive statements about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of ATNM during the specified class period are encouraged to register for the class action by May 27, 2025 [3]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in this case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].